PARP Inhibition Modulates GAPDH Activity in a Diabetic Mouse Model of Hind Limb Ischemia–Reperfusion  by Boulom, Valy et al.
model was then created to determine if the operative approach indepen-
dently influenced outcome.
Results: There were 485 patients (385 CS [79%]; 100 AFB/MEVP
[21%]). The cohorts iffered in that the AFB/MEVP group was younger
(65.8  12.5 vs 70.9  9.7 years; P  .001), had more extent I/II
aneurysms (66% vs 0.1%; P  .0005), and had more chronic dissections
(30.3% vs 18.9%; P  .0018). Operative variables differed in that the
AFB/MEVP cohort had longer operative times (434  112 vs 324  98
minutes; P  .001) and higher blood turnover (6028  3473 vs 3581 
3111 mL; P .0001). There was no difference in AFB/MEPB vs CS for the
rate of intraoperative death (1.0% vs 0.05%; P  .050), length of intensive
care unit stay (9.6  8.6 vs 9.5  12.3 days CS; P  .095), and hospital
length of stay (19.9 12.6 vs 21.6 23.5 days; P .049). The composite
perioperative death and paraplegia rate was lower in the AFB/MEVP cohort
(7% vs 19%; P  .0004). The multivariate model for predictors of the
composite outcome showed that AFB/MEVP was protective (odds ratio,
0.039 [0.17, 0.9]; P  .0028). Long-term (4-year) survival was also
improved in the AFB/MEVP group (73%  6% vs 60%  3%; P  .0004).
Conclusions: AFB/MEVP is an independent predictor of reduced
perioperative death and paraplegia as well as improved long-term survival in
patients undergoing repair of type I-III TAA and is the preferred operative
strategy over CS.
MidtermOutcomes of Thoracic Endovascular Stent Repair for Chronic
Type B Aortic Dissection With Aneurysmal Degeneration
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Introduction and objectives: The U.S. Food and Drug Administra-
tion has approved devices for endovascular management of thoracic aortic
degenerative pathology (TEVAR); however, few data exist describing the
outcome of TEVAR for aneurysms due to chronic type B aortic dissection
(An-cTBAD). This study was undertaken to define the results of endovas-
cular treatment of An-cTBAD.
Methods: A retrospective analysis of all patients treated for An-cTBAD
was performed. Patient demographics, procedural outcomes, and anatomic
covariates were aggregated. Reintervention and mortality were estimated
using life-tables.
Results: Eighty patients (69 men [87%]) underwent TEVAR to treat
An-cTBAD with mean  standard deviation age 58  13 years and median
follow-up of 28 months (range 1-74 months). Median time from diagnosis
of TBAD to TEVAR was 27 months (range, 1-74 months). Prior aortic
root/arch replacement had occurred in 29% (n 23) at a median interval of
28.5 months (range, 0.5-312 months). Mean aneurysm diameter was 62.0 
9.9 mm. Coverage occurred proximal to zone 3 in 75% (n  60) of
patients, and 24% (n  19) underwent a carotid-subclavian bypass or arch
debranching procedure. Spinal drains were used in 81% (preoperatively in
73% [n 59]; and postoperatively in 8% [n 6]). Length of stay was 6.5
4.7 days, with a composite morbidity of 26% and in-hospital mortality of
2.5% (n  2). Spinal cord ischemia developed in 9% (n  7), with a
permanent deficit observed in 6.2% (n 5). Aneurysm diameter reduced or
stabilized in 65%. The false lumen thrombosed completely within the
thoracic aorta in 52%, and reintervention within the treated aortic segment
was required in 16% (n  13). At 1 year, freedom from reintervention was
75% and mortality was 83%.
Conclusions:TEVAR for An-cTBAD can be performed safely, but spinal
cord ischemia rates may be higher than previously reported. Reintervention
rates are acceptable; however, lack of uniform aneurysm diameter reduction and
false lumen thrombosis underscore the need for longer-term follow-up and
greater patient numbers to determine procedural durability and efficacy.
Blunt Thoracic Aortic Injury: A 14-Year Experience at a Level 1
Trauma Center
Jennifer Watson, Jeffery Slaiby, Manuel Garcia Toca, Edward Marcaccio,
Tze Tec Chong. Brown University/Rhode Island Hospital, Providence, RI
Introduction and objectives: To review the natural history of blunt
thoracic aortic trauma (BTAT) over a 14-year period at our level 1 trauma
center and to compare open vs endovascular treatment.
Methods: All patients with BTAT presenting to a level 1 trauma center
from 1998 to 2011 were included in a retrospective analysis. Multiple data
points and short-term and moderate-term outcomes were ascertained by record
review.
Results: The review identified 129 patients with BTAT. Of these, 32
(25%) were dead on arrival, 38 (29%) underwent an emergency department
thoracotomy and died, 33 (25.5%) underwent open repair, 14 (11%) under-
went endovascular repair, nine (7%) underwent a combination of proce-
dures, and three (2%) were managed nonoperatively. Demographics, includ-
ing injury severity score (average, 36) and revised trauma score (average, 9),
were similar between the open and endovascular groups. The location of
injury was also similar between groups (89% of injuries occurring at or 2
cm of the left subclavian artery). Rates of stroke, myocardial infarction, renal
failure, and paralysis, length of stay (LOS), and 30-day mortality were
decreased in the endovascular repair group compared with the open repair
group (Table). Intraoperative time (P  .053), need for intraoperative red
blood cell transfusion (P .001), and estimated blood loss (P.001) were
all decreased in the endovascular group vs the open group. The average LOS
for patients treated with endovascular repair was 15 vs 24 days in those
treated with open repair (P  .003).
Conclusions: The incidence of BTAT is low but associated mortality is
significant. During the 14-year period, there was a clear change in manage-
ment preference from open repair to endovascular repair. Outcomes includ-
ing stroke, myocardial infarction, renal failure, paralysis, LOS, and death
seem to be reduced in the endovascular group.
Table. Comparison of complications between the open and endovascular
repair groups
Complications 30 days
Repair group, No. (%)
POpen Endovascular
Death 14 (42) 1 (7) .012
Myocardial infarction 2 (6) 0 .257
Stroke 3 (9) 1 (7) .257
Renal failure requiring
HD
3 (9) 0 .143
Paralysis 2 (6) 0 .473
Stent collapse . . . 1 (7) . . .
Thrombospondin-1 Differentially Regulates MicroRNAs in Vascular
Smooth Muscle Cells
Kristopher G. Maier,12 Brian Ruhle,2 Jeffrey J. Stein,12 Karen L. Gentile,2
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Introduction and objectives: Thrombospondin-1 (TSP-1) is an im-
portant regulator of vascular smooth muscle cell (VSMC) physiology and
gene expression. MicroRNAs (miRNA), which have emerged as potent
regulators of cell function, are small molecules that regulate protein trans-
lation. miRNAs are be involved in intimal hyperplasia and atherosclerosis
and are upregulated in the vasculature in diabetes. The purpose of this study
was to identify miRNAs regulated by TSP-1 in VSMCs.
Methods: Human VSMCs were used. Both treatment groups con-
sisted of three separate experiments, and the miRNA microarray was per-
formed in triplicate for each sample. Cells were treated for 6 hours with basal
media or TSP-1, both supplemented with 0.2% fetal bovine serum. Cells
were snap frozen and RNA was extracted. An Affymetrix GeneChip miRNA
array analysis was performed. Data was analyzed by analysis of variance with
significance set at P  .05.
Results: TSP-1 upregulated 11 miRNAs and downregulated 23 miR-
NAs in VSMCs (P  .05). The most upregulated miRNA was miR-224
(1.57-fold). Also increased were miR-224 and miR-200c. The miRNA most
downregulated by TSP-1 was miR-17*, which was decreased by 2.25-fold.
Interestingly, 14 of the miRNAs altered were of the miRNA* strand.
Conclusions:The present study examined the effect of TSP-1 on miRNA
expression in VSMCs. miRNAs regulate protein expression at the level of
translation and may represent a significant mechanism by which TSP-1 regulates
VSMC function. In addition, several of the miRNAs identified, such as miR-224
and miR-200c, have a role in vascular function. The miR-17 family, which
exhibited reduced expression in this study, is known to inhibit cell proliferation
and migration. We further found that several miRNA* strands were altered. The
miRNA* strand, once thought to be the inactive complimentary strand of the
mature miRNA, is now appreciated to regulate cellular function and may
represent new targets for modifying TSP-1 signaling.
PARP Inhibition Modulates GAPDH Activity in a Diabetic Mouse
Model of Hind Limb Ischemia–Reperfusion
Valy Boulom,1 Chandler A. Long,2 Rahmi Oklu,3 Junaid Y. Malek,4
Hyung-Jin Yoo,4 Maxime Raux,4 Michael T. Watkins,4 Hassan Albadawi4.
1Sinai Hospital, Baltimore, Md; 2University of Tennessee, Knoxville, Tenn;
3Massachusetts General Hospital, Boston, Mass; 4Henri Mondor Hospital,
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Introduction and objectives: Previous work has demonstrated that
poly (ADP-ribose) polymerase (PARP) inhibition confers protection on
skeletal muscle ischemia–reperfusion (IR) injury in diabetic mice. Published
reports, including a model of renal IR injury in normal nondiabetic mice,
have shown that poly (ADP-ribosylation) of the critical glycolytic enzyme
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) results in reduced
enzyme activity, thereby reducing energy metabolites. This study aims to
determine whether PARP inhibition modulates the activity and level of poly
(ADP-ribosylation) of GAPDH, along with energy substrates within dia-
betic skeletal muscle after IR.
Methods: Two groups of db/db mice underwent 1.5 hours of unilat-
eral hind limb ischemia, followed by 24 hours reperfusion. The treatment
group (PJ) received 6 dosages of 30 mg/kg of PJ34, a PARP inhibitor, at
5 minutes before reperfusion, at 15 minutes, and at 2, 6, 12, and 18 hours
after reperfusion. The untreated group received equivalent volumes of
lactated Ringer’s (LR) vehicle at the same time points. Uninjured sham mice
were used as the control. Hind limb skeletal muscle tissue was harvested at
24 hours reperfusion to evaluate PARP and GAPDH activity, total GAPDH
expression and poly (ADP-ribosylated) GAPDH, in addition to skeletal
muscle ATP and lactate.
Results: PJ34 treatment significantly reduced PARP activity and in-
creased GAPDH activity relative to LR at 24 hours’ reperfusion (Table).
GAPDH expression was significantly lower in the PJ group. Poly (ADP-
ribosylation) of GAPDH was significantly reduced in the PJ group. PJ34
treatment significantly increased skeletal muscle ATP and lactate compared
with LR.
Conclusions: These data indicate that PARP inhibition by PJ34 in-
creased GAPDH activity, tissue lactate, and ATP, and decreased poly (ADP-
ribosylation) of GAPDH after IR. The resulting increase in tissue ATP and
lactate may provide mechanistic insight into how PARP inhibition mediates
protection against skeletal muscle IR injury.
Table.
LR PJ
P(n  6-16) (n  6-10)
PARP activity (% control) 300  48 221  20 .0043
GAPDH activity (U/2-
mg protein) 0.31  0.04 0.5  0.04 .0005
GAPDH expression (%
control) 122.5  8 94  6 .0008
GAPDH poly (ADP-
ribosylation) (AU) 1.5  0.23 0.41  0.13 .0002
Muscle ATP (nmol/g
tissue) 0.3  0.1 0.84  0.3 .0046
Muscle lactate (g/g
tissue) 229  10 375.6  48 .00004
Brief Preoperative Dietary Restriction Affords Protection From Inti-
mal Hyperplasia in a Novel Murine Model
Christine R. Mauro,1 Ming Tao,2 Peng Yu,2 James R. Mitchell,3 C. Keith
Ozaki2. 1Beth Israel Deaconess Medical Center, Boston, Mass; 2Brigham
and Women’s Hospital, Boston, Mass; 3Harvard School of Public Health,
Boston, Mass
Introduction and objectives: Dietary restriction (DR; reduced food
intake without malnutrition) effectively reduces the acute response to sur-
gical stress in preclinical models likely by anti-inflammatory and antioxidant
mechanisms. Leveraging a novel murine carotid focal stenosis model, we
tested the hypothesis that DR would attenuate the arterial intimal hyperpla-
sia (IH) response.
Methods: A focal stenosis in 8-week-old C57BL/6J mice was created
by placing a 9-0 nylon suture tie around the distal common carotid artery
and an external 35-gauge needle mandrel (outer diameter, .014 mm) and
then removing the mandrel (78% lumen diameter reduction, 90% flow
reduction). Animals received 60 kcal% fat diet-induced obesity (DIO) chow
at baseline, and then the same chow (n  10) or 10 kcal% fat normal chow
(NC; n  10) postoperatively. One group (n  20) had a water-only fast
(DR) 72 hours before focal stenosis creation, then NC. Tissues were
perfusion-fixed 4 weeks later. Immunohistochemical staining was performed
for CD31, F4/80, and -actin.
Results: Switching to NC postoperatively reduced IH (P  .001) and
adventitial macrophages (P  .05; Fig). Brief preoperative DR even further
attenuated IH (P  .001) and yielded increased IH neovessel formation
(P  .05).
Conclusions: This murine focal carotid stenosis model offers a
straightforward method to dissect the mechanisms of arterial IH. Postoper-
ative NC rather than DIO attenuates IH. Short-term preoperative DR
further downregulates the longer-term arterial IH response, and this is
associated with less macrophage infiltration and increased IH neovascularity.
These dietary manipulations potentially offer a practical approach to extend
the durability of acute vascular interventions.
Composite Electrospun Polyethylene Terephthalate: A Method To-
wards Improving Graft Patency
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Introduction and objectives: Intimal hyperplasia (IH) remains the
leading cause for prosthetic arterial graft failure. A composite of electrospun
polymers, such as nondegradable polymer, polyethylene terephthalate
(ePET) with a degradable polymer, and polyglycolic acid (PGA) infused
with biologically active material that can prevent the development of IH is an
appealing alternative to other clinically used grafts made of polytetrafluoro-
ethylene (PTFE).
Methods: Electrospun grafts were synthesized from ePET, copolymer
of ePET/ePGA (90:10, PET/PGA mixture resulting in a single fiber), or
cospun ePET/ePGA (90:10, individual PET and PGA fibers interspersed).
Pieces of grafts (5 mm2) were incubated in saline at 37°C for 7, 14, and 21
days and imaged using scanning electron microscopy. Attachment and
viability of human aortic smooth muscle cells (HAoSMC) seeded onto the
materials were analyzed 3 and 48 hours later, and comparisons were made
with HAoSMCs seeded on PTFE. In addition, siGLO Red (control short
interfering [si]RNA with DyLight-547 fluorescent tag) was infused into
PGA fibers of the cospun graft and siRNA degradation was observed using
confocal microscopy.
Results: Scanning electron microscopy images indicated breakage of
ePET/ePGA copolymer fibers at days 14 and 21, whereas the cospun
ePET/ePGA material showed intact ePET fibers and fragmented ePGA
fibers. Compared with PTFE, HAoSMC demonstrated a greater affinity and
viability towards electrospun materials and significantly more to cospun
ePET/ePGA. Integration of siGLO Red into PGA fibers of cospun grafts
was successful, and red fluorescent density decreased 90% in 2 weeks,
indicating release of siGLO Red.
Conclusions: Cospun ePET/ePGA remained intact after PGA degra-
dation, whereas the copolymer showed fiber breaks and fragility, making
cospun material more favorable as prosthetic arterial bypass grafts. Electro-
spun composite grafts did not impair HAoSMC attachment and growth.
siGLO Red was successfully incorporated and released from cospun ePET/
ePGA. Electrospun composite grafts can act as a delivery platform for gene
silencing to control IH.
Midterm Results of a Pilot Study on Bone Marrow Aspirate Concen-
trate in Critical Limb Ischemia
Mark D. Iafrati, The BMAC Investigators Tufts Medical Center, Boston,
Mass
Introduction and objectives: Bone marrow aspirate concentrate
(BMAC), which contains cells with regenerative properties, has been studied
as a treatment for critical limb ischemia (CLI). We report the intermediate-
term results of a BMAC pilot study.
Methods: A prospective, randomized, placebo-controlled trial of
BMAC in CLI was conducted in Rutherford 4 (rest pain) and Rutherford 5
(limited tissue loss) patients. All patients were poor candidates for conven-
tional revascularization due to anatomic or physiologic considerations.
Patients were treated in a single session with aspiration of bone marrow and
preparation of BMAC injectate or placebo (peripheral blood). Forty injec-
tions were made percutaneously into the ischemic extremity and distributed
in a linear fashion along the ischemic gradient. An initial analysis previously
reported 3-month data and we are now reporting the 12-month (interme-
diate) follow-up.
Results:Of 48 patients who were treated (mean age, 69.5 years; range,
42-93), 18 (37.5%) were Rutherford 4 and 30 (62.5%) were Rutherford 5.
Fig.
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